Direct and Indirect Effect of TGFβ on Treg Transendothelial Recruitment in HCC Tissue Microenvironment

dc.contributor.authorDituri, Francesco
dc.contributor.authorMancarella, Serena
dc.contributor.authorSerino, Grazia
dc.contributor.authorChaoul, Nada
dc.contributor.authorLupo, Luigi Giovanni
dc.contributor.authorVilla, Erica
dc.contributor.authorFabregat Romero, Isabel
dc.contributor.authorGiannelli, Gianluigi
dc.date.accessioned2021-12-09T08:54:37Z
dc.date.available2021-12-09T08:54:37Z
dc.date.issued2021-10-29
dc.date.updated2021-12-02T08:36:05Z
dc.description.abstractThe balance between anti-tumor and tumor-promoting immune cells, such as CD4+ Th1 and regulatory T cells (Tregs), respectively, is assumed to dictate the progression of hepatocellular carcinoma (HCC). The transforming growth factor beta (TGFβ) markedly shapes the HCC microenvironment, regulating the activation state of multiple leukocyte subsets and driving the differentiation of cancer associated fibroblasts (CAFs). The fibrotic (desmoplastic) reaction in HCC tissue strongly depends on CAFs activity. In this study, we attempted to assess the role of TGFβ on transendothelial migration of Th1-oriented and Treg-oriented CD4+ T cells via a direct or indirect, CAF-mediated mechanisms, respectively. We found that the blockage of TGFβ receptor I-dependent signaling in Tregs resulted in impaired transendothelial migration (TEM) of these cells. Interestingly, the secretome of TGFβ-treated CAFs inhibited the TEM of Tregs but not Th1 cells, in comparison to the secretome of untreated CAFs. In addition, we found a significant inverse correlation between alpha-SMA and FoxP3 (marker of Tregs) mRNA expression in a microarray analysis involving 78 HCCs, thus suggesting that TGFβ-activated stromal cells may counteract the trafficking of Tregs into the tumor. The apparent dual behavior of TGFβ as both pro- and anti-tumorigenic cytokines may add a further level of complexity to the mechanisms that regulate the interactions among cancerous, stromal, and immune cells within HCC, as well as other solid tumors, and contribute to better manipulation of the TGFβ signaling as a therapeutic target in HCC patients.
dc.format.extent13 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1422-0067
dc.identifier.pmid34769191
dc.identifier.urihttps://hdl.handle.net/2445/181713
dc.language.isoeng
dc.publisherMDPI AG
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms222111765
dc.relation.ispartofInternational Journal of Molecular Sciences, 2021, vol. 22, num. 21
dc.relation.urihttps://doi.org/10.3390/ijms222111765
dc.rightscc by (c) Dituri, Francesco et al, 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationFactors de creixement
dc.subject.classificationCàncer de fetge
dc.subject.otherGrowth factors
dc.subject.otherLiver cancer
dc.titleDirect and Indirect Effect of TGFβ on Treg Transendothelial Recruitment in HCC Tissue Microenvironment
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
ijms-22-11765-v3.pdf
Mida:
3.07 MB
Format:
Adobe Portable Document Format